Goldstein Laura H, Robinson Emily J, Mellers John D C, Stone Jon, Carson Alan, Reuber Markus, Medford Nick, McCrone Paul, Murray Joanna, Richardson Mark P, Pilecka Izabela, Eastwood Carole, Moore Michele, Mosweu Iris, Perdue Iain, Landau Sabine, Chalder Trudie
Department of Psychology, King's College London, London, UK.
Department of Biostatistics and Health Informatics, King's College London, London, UK; Institute of Psychiatry, Psychology and Neuroscience, and School of Population Health and Environmental Sciences, King's College London, London, UK.
Lancet Psychiatry. 2020 Jun;7(6):491-505. doi: 10.1016/S2215-0366(20)30128-0. Epub 2020 May 20.
Dissociative seizures are paroxysmal events resembling epilepsy or syncope with characteristic features that allow them to be distinguished from other medical conditions. We aimed to compare the effectiveness of cognitive behavioural therapy (CBT) plus standardised medical care with standardised medical care alone for the reduction of dissociative seizure frequency.
In this pragmatic, parallel-arm, multicentre randomised controlled trial, we initially recruited participants at 27 neurology or epilepsy services in England, Scotland, and Wales. Adults (≥18 years) who had dissociative seizures in the previous 8 weeks and no epileptic seizures in the previous 12 months were subsequently randomly assigned (1:1) from 17 liaison or neuropsychiatry services following psychiatric assessment, to receive standardised medical care or CBT plus standardised medical care, using a web-based system. Randomisation was stratified by neuropsychiatry or liaison psychiatry recruitment site. The trial manager, chief investigator, all treating clinicians, and patients were aware of treatment allocation, but outcome data collectors and trial statisticians were unaware of treatment allocation. Patients were followed up 6 months and 12 months after randomisation. The primary outcome was monthly dissociative seizure frequency (ie, frequency in the previous 4 weeks) assessed at 12 months. Secondary outcomes assessed at 12 months were: seizure severity (intensity) and bothersomeness; longest period of seizure freedom in the previous 6 months; complete seizure freedom in the previous 3 months; a greater than 50% reduction in seizure frequency relative to baseline; changes in dissociative seizures (rated by others); health-related quality of life; psychosocial functioning; psychiatric symptoms, psychological distress, and somatic symptom burden; and clinical impression of improvement and satisfaction. p values and statistical significance for outcomes were reported without correction for multiple comparisons as per our protocol. Primary and secondary outcomes were assessed in the intention-to-treat population with multiple imputation for missing observations. This trial is registered with the International Standard Randomised Controlled Trial registry, ISRCTN05681227, and ClinicalTrials.gov, NCT02325544.
Between Jan 16, 2015, and May 31, 2017, we randomly assigned 368 patients to receive CBT plus standardised medical care (n=186) or standardised medical care alone (n=182); of whom 313 had primary outcome data at 12 months (156 [84%] of 186 patients in the CBT plus standardised medical care group and 157 [86%] of 182 patients in the standardised medical care group). At 12 months, no significant difference in monthly dissociative seizure frequency was identified between the groups (median 4 seizures [IQR 0-20] in the CBT plus standardised medical care group vs 7 seizures [1-35] in the standardised medical care group; estimated incidence rate ratio [IRR] 0·78 [95% CI 0·56-1·09]; p=0·144). Dissociative seizures were rated as less bothersome in the CBT plus standardised medical care group than the standardised medical care group (estimated mean difference -0·53 [95% CI -0·97 to -0·08]; p=0·020). The CBT plus standardised medical care group had a longer period of dissociative seizure freedom in the previous 6 months (estimated IRR 1·64 [95% CI 1·22 to 2·20]; p=0·001), reported better health-related quality of life on the EuroQoL-5 Dimensions-5 Level Health Today visual analogue scale (estimated mean difference 6·16 [95% CI 1·48 to 10·84]; p=0·010), less impairment in psychosocial functioning on the Work and Social Adjustment Scale (estimated mean difference -4·12 [95% CI -6·35 to -1·89]; p<0·001), less overall psychological distress than the standardised medical care group on the Clinical Outcomes in Routine Evaluation-10 scale (estimated mean difference -1·65 [95% CI -2·96 to -0·35]; p=0·013), and fewer somatic symptoms on the modified Patient Health Questionnaire-15 scale (estimated mean difference -1·67 [95% CI -2·90 to -0·44]; p=0·008). Clinical improvement at 12 months was greater in the CBT plus standardised medical care group than the standardised medical care alone group as reported by patients (estimated mean difference 0·66 [95% CI 0·26 to 1·04]; p=0·001) and by clinicians (estimated mean difference 0·47 [95% CI 0·21 to 0·73]; p<0·001), and the CBT plus standardised medical care group had greater satisfaction with treatment than did the standardised medical care group (estimated mean difference 0·90 [95% CI 0·48 to 1·31]; p<0·001). No significant differences in patient-reported seizure severity (estimated mean difference -0·11 [95% CI -0·50 to 0·29]; p=0·593) or seizure freedom in the last 3 months of the study (estimated odds ratio [OR] 1·77 [95% CI 0·93 to 3·37]; p=0·083) were identified between the groups. Furthermore, no significant differences were identified in the proportion of patients who had a more than 50% reduction in dissociative seizure frequency compared with baseline (OR 1·27 [95% CI 0·80 to 2·02]; p=0·313). Additionally, the 12-item Short Form survey-version 2 scores (estimated mean difference for the Physical Component Summary score 1·78 [95% CI -0·37 to 3·92]; p=0·105; estimated mean difference for the Mental Component Summary score 2·22 [95% CI -0·30 to 4·75]; p=0·084), the Generalised Anxiety Disorder-7 scale score (estimated mean difference -1·09 [95% CI -2·27 to 0·09]; p=0·069), and the Patient Health Questionnaire-9 scale depression score (estimated mean difference -1·10 [95% CI -2·41 to 0·21]; p=0·099) did not differ significantly between groups. Changes in dissociative seizures (rated by others) could not be assessed due to insufficient data. During the 12-month period, the number of adverse events was similar between the groups: 57 (31%) of 186 participants in the CBT plus standardised medical care group reported 97 adverse events and 53 (29%) of 182 participants in the standardised medical care group reported 79 adverse events.
CBT plus standardised medical care had no statistically significant advantage compared with standardised medical care alone for the reduction of monthly seizures. However, improvements were observed in a number of clinically relevant secondary outcomes following CBT plus standardised medical care when compared with standardised medical care alone. Thus, adults with dissociative seizures might benefit from the addition of dissociative seizure-specific CBT to specialist care from neurologists and psychiatrists. Future work is needed to identify patients who would benefit most from a dissociative seizure-specific CBT approach.
National Institute for Health Research, Health Technology Assessment programme.
分离性癫痫发作是类似癫痫或晕厥的阵发性事件,具有可使其与其他病症相区分的特征。我们旨在比较认知行为疗法(CBT)加标准化医疗护理与单纯标准化医疗护理在降低分离性癫痫发作频率方面的有效性。
在这项实用、平行组、多中心随机对照试验中,我们最初在英格兰、苏格兰和威尔士的27个神经病学或癫痫服务机构招募参与者。在过去8周内有分离性癫痫发作且在过去12个月内无癫痫发作的成年人(≥18岁),随后在经过精神科评估后,从17个联络或神经精神科服务机构中通过基于网络的系统随机分配(1:1),接受标准化医疗护理或CBT加标准化医疗护理。随机分组按神经精神科或联络精神科招募地点进行分层。试验管理者、首席研究员、所有治疗临床医生和患者知晓治疗分配情况,但结果数据收集者和试验统计学家不知晓治疗分配情况。患者在随机分组后6个月和12个月进行随访。主要结局是在12个月时评估的每月分离性癫痫发作频率(即前4周的频率)。在12个月时评估的次要结局包括:癫痫发作严重程度(强度)和困扰程度;过去6个月中最长的无癫痫发作期;过去3个月中的完全无癫痫发作;相对于基线癫痫发作频率降低超过50%;分离性癫痫发作的变化(由他人评定);健康相关生活质量;心理社会功能;精神症状、心理困扰和躯体症状负担;以及改善和满意度的临床印象。根据我们的方案,结局的p值和统计学显著性未进行多重比较校正。在对缺失观察值进行多重插补的意向性治疗人群中评估主要和次要结局。本试验已在国际标准随机对照试验注册库(ISRCTN05681227)和美国国立医学图书馆临床试验注册库(NCT02325544)注册。
在2015年1月16日至2017年5月31日期间,我们随机分配368例患者接受CBT加标准化医疗护理(n = 186)或单纯标准化医疗护理(n = 182);其中313例在12个月时有主要结局数据(CBT加标准化医疗护理组186例患者中的156例[84%],标准化医疗护理组182例患者中的157例[86%])。在12个月时,两组之间每月分离性癫痫发作频率无显著差异(CBT加标准化医疗护理组中位数为4次发作[IQR 0 - 20],标准化医疗护理组为7次发作[1 - 35];估计发病率比[IRR]为0.78[95%CI 0.56 - 1.09];p = 0.144)。与标准化医疗护理组相比,CBT加标准化医疗护理组中分离性癫痫发作被评定为困扰程度较轻(估计平均差为 - 0.53[95%CI - 0.97至 - 0.08];p = 0.020)。CBT加标准化医疗护理组在过去6个月中有更长的分离性癫痫发作无发作期(估计IRR为1.64[95%CI 1.22至2.20];p = 0.001),在欧洲五维健康量表-5级今日健康视觉模拟量表上报告的健康相关生活质量更好(估计平均差为6.16[95%CI 1.48至10.84];p = 0.010),在工作和社会适应量表上心理社会功能受损较少(估计平均差为 - 4.12[95%CI - 6.35至 - 1.89];p < 0.001),在常规评估临床结局-10量表上总体心理困扰比标准化医疗护理组少(估计平均差为 - 1.65[95%CI - 2.96至 - 0.35];p = 0.013),在改良的患者健康问卷-15量表上躯体症状较少(估计平均差为 - 1.67[95%CI - 2.90至 - 0.44];p = 0.008)。患者报告的12个月时的临床改善情况,CBT加标准化医疗护理组比单纯标准化医疗护理组更大(估计平均差为0.66[95%CI 0.26至1.04];p = 0.001),临床医生报告的也是如此(估计平均差为0.47[95%CI 0.21至0.73];p < 0.001),并且CBT加标准化医疗护理组对治疗的满意度高于标准化医疗护理组(估计平均差为0.90[95%CI 0.48至1.31];p < 0.001)。两组之间患者报告的癫痫发作严重程度(估计平均差为 - 0.11[95%CI - 0.50至0.29];p = 0.593)或研究最后3个月的无癫痫发作情况(估计比值比[OR]为1.77[95%CI 0.93至3.37];p = 0.083)无显著差异。此外,与基线相比分离性癫痫发作频率降低超过50%的患者比例无显著差异(OR为1.27[95%CI 0.80至2.02];p = 0.313)。此外,两组之间12项简短健康调查问卷-第2版评分(躯体成分汇总评分的估计平均差为1.78[95%CI - 0.37至3.92];p = 0.105;精神成分汇总评分的估计平均差为2.22[95%CI - 0.30至4.75];p = 0.084)、广泛性焦虑障碍-7量表评分(估计平均差为 - 1.09[95%CI - 2.27至0.09];p = 0.069)和患者健康问卷-9量表抑郁评分(估计平均差为 - 1.10[95%CI - 2.41至0.21];p = 0.099)无显著差异。由于数据不足无法评估分离性癫痫发作的变化(由他人评定)。在12个月期间,两组之间不良事件数量相似:CBT加标准化医疗护理组186例参与者中的57例(31%)报告了97例不良事件,标准化医疗护理组182例参与者中的53例(29%)报告了79例不良事件。
CBT加标准化医疗护理与单纯标准化医疗护理相比,在降低每月癫痫发作频率方面无统计学显著优势。然而,与单纯标准化医疗护理相比,CBT加标准化医疗护理在一些临床相关的次要结局方面有改善。因此,患有分离性癫痫发作的成年人可能会从在神经科医生和精神科医生的专科护理基础上增加针对分离性癫痫发作的CBT中获益。未来需要开展工作以确定最能从针对分离性癫痫发作的CBT方法中获益的患者。
英国国家卫生研究院卫生技术评估项目。